The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Health Rounds newsletter excerpt has been corrected to indicate in the headline and the first item of the story that Sanofi ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Researchers at Mayo Clinic are exploring the use of a new drug called ataciguat to manage AVS. Results from preclinical and clinical studies, published in Circulation, show that ataciguat has the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Opens in a new tab or window The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis ...

The drug ataciguat has been tested in early and mid-stage trials of patients with moderate aortic valve stenosis. The most recent 23-patient trial showed a nearly 70% reduction in aortic valve ...